Evaxion A (EVAX) Enterprise Value (2019 - 2026)
Evaxion A's (EVAX) quarterly Enterprise Value came in at -$18.4 million in Q1 2026, down 3.35% YoY from -$19.1 million in Q1 2025, and up 20.63% on a QoQ basis from -$23.2 million in Q4 2025.
Evaxion A (EVAX) Enterprise Value (2019 - 2026) Analysis & Trends
Evaxion A (EVAX) has 8 years of Enterprise Value data on file, last reported at -$18.4 million in Q1 2026.
- Quarterly Enterprise Value fell 3.35% year-over-year to -$18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.4 million (down 3.35% YoY) and the FY2025 annual result came in at -$23.2 million, down 290.36% from the prior year.
- Enterprise Value advanced to -$18.4 million in Q1 2026, from -$23.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$11731.0 in Q1 2024 to a low of -$31.4 million in Q1 2022.
- A 5-year average of -$13.3 million and a median of -$11.9 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 99.89% — and 2025, when it plunged 152001.27%.
- Tracing EVAX's Enterprise Value over 5 years: stood at -$13.2 million in 2022, then surged by 57.65% to -$5.6 million in 2023, then retreated by 6.61% to -$6.0 million in 2024, then plunged by 290.36% to -$23.2 million in 2025, then gained by 20.63% to -$18.4 million in 2026.
- The last three Enterprise Value figures came in at -$18.4 million (Q1 2026), -$23.2 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Evaxion A | 27.69 Mn | 27.69 Mn | - | -18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.44 Mn |
| Dec 31, 2025 | -23.23 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Jun 30, 2025 | -14.75 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Dec 31, 2024 | -5.95 Mn |
| Jun 30, 2024 | -7.99 Mn |
| Mar 31, 2024 | -11,731.00 |
| Dec 31, 2023 | -5.58 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -7.12 Mn |
| Mar 31, 2023 | -10.24 Mn |
| Dec 31, 2022 | -13.18 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -25.25 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -32.17 Mn |
| Sep 30, 2021 | -11.94 Mn |
| Jun 30, 2021 | -18.80 Mn |
| Mar 31, 2021 | -26.96 Mn |